Immune Response and Vaccination Effectiveness against Mycobacterium tuberculosis Infection
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Innate and Adaptive Immunity in Vaccination".
Deadline for manuscript submissions: closed (30 September 2023) | Viewed by 3423
Special Issue Editor
Interests: vaccines; immunotherapy; immunopathology; experimental modeling; tuberculosis; infectious diseases
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Tuberculosis is still a major challenge for both humans and animals. BCG, the only vaccine that is currently available on the market, was designed 100 years ago. The lack of correlates of protection is one of the major hallmarks hampering any quick and feasible development. There is a need for a better understanding of the natural history of TB in order to design reliable biomarkers. This should include not only ad hoc clinical trials considering the One Health approach, but also information obtained from contact studies, including WGS from M. tuberculosis strains for better surveillance, to evaluate natural mechanisms of protection against active TB. On the other hand, new candidates for both human and animal protection must fill the pipeline, so there is a need for new candidates, better experimental models for testing them, and the design of new tools (including in silico) to optimize clinical trials.
Prof. Dr. Pere-Joan Cardona
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- tuberculosis
- vaccine
- immunotherapy
- immunomodulation
- biomarkers
- immunopathology
- correlates of protection
- antibodies
- T cells
- Tregs
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.